A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Brazikumab (Primary) ; Brazikumab (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EXPEDITION
- Sponsors AbbVie; Allergan; AstraZeneca
- 03 Jul 2023 Planned End Date changed from 21 Jan 2025 to 13 Oct 2023.
- 03 Jul 2023 Planned primary completion date changed from 14 Nov 2023 to 13 Oct 2023.
- 01 Jun 2023 Status changed from recruiting to discontinued, according to a AstraZeneca media release.